188 related articles for article (PubMed ID: 38149948)
1. Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy.
Kapadia CD; Rosas G; Thakkar SG; Wu M; Torrano V; Wang T; Grilley BJ; Heslop HE; Ramos CA; Goodell MA; Lulla PD
Cytotherapy; 2024 Mar; 26(3):261-265. PubMed ID: 38149948
[TBL] [Abstract][Full Text] [Related]
2. Low-Frequency
Seipel K; Frey M; Nilius H; Akhoundova D; Banz Y; Bacher U; Pabst T
Curr Oncol; 2023 Dec; 30(12):10463-10476. PubMed ID: 38132396
[TBL] [Abstract][Full Text] [Related]
3. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
Saini NY; Swoboda DM; Greenbaum U; Ma J; Patel RD; Devashish K; Das K; Tanner MR; Strati P; Nair R; Fayad L; Ahmed S; Lee HJ; Iyer SP; Steiner R; Jain N; Nastoupil L; Loghavi S; Tang G; Bassett RL; Jain P; Wang M; Westin JR; Green MR; Sallman DA; Padron E; Davila ML; Locke FL; Champlin RE; Garcia-Manero G; Shpall EJ; Kebriaei P; Flowers CR; Jain MD; Wang F; Futreal AP; Gillis N; Neelapu SS; Takahashi K
Blood Cancer Discov; 2022 Sep; 3(5):385-393. PubMed ID: 35533245
[TBL] [Abstract][Full Text] [Related]
4. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
Front Immunol; 2022; 13():858021. PubMed ID: 35432352
[TBL] [Abstract][Full Text] [Related]
6. Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.
Eder LN; Martinovic D; Mazzeo P; Ganster C; Hasenkamp J; Thomson J; Trummer A; Haase D; Wulf G
Curr Oncol; 2023 Jan; 30(1):1146-1150. PubMed ID: 36661736
[TBL] [Abstract][Full Text] [Related]
7. Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients.
Panagiota V; Kerschbaum JF; Penack O; Stein CM; Arends CM; Koenecke C; Strzelecka PM; Kloos A; Wiegand L; Lasch A; Altwasser R; Halik A; Gabdoulline R; Thomson J; Weibl K; Franke GN; Berger C; Hasenkamp J; Ayuk F; Na IK; Beutel G; Keller U; Bullinger L; Wulf GG; Kröger N; Vucinic V; Heuser M; Damm F
Hemasphere; 2023 Oct; 7(10):e957. PubMed ID: 37799345
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA; Grover NS; Beaven AW; Lulla PD; Wu MF; Ivanova A; Wang T; Shea TC; Rooney CM; Dittus C; Park SI; Gee AP; Eldridge PW; McKay KL; Mehta B; Cheng CJ; Buchanan FB; Grilley BJ; Morrison K; Brenner MK; Serody JS; Dotti G; Heslop HE; Savoldo B
J Clin Oncol; 2020 Nov; 38(32):3794-3804. PubMed ID: 32701411
[TBL] [Abstract][Full Text] [Related]
9. The crossroads of cancer therapies and clonal hematopoiesis.
Singh A; Balasubramanian S
Semin Hematol; 2024 Feb; 61(1):16-21. PubMed ID: 38403501
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
11. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.
Miller PG; Sperling AS; Brea EJ; Leick MB; Fell GG; Jan M; Gohil SH; Tai YT; Munshi NC; Wu CJ; Neuberg DS; Maus MV; Jacobson C; Gibson CJ; Ebert BL
Blood Adv; 2021 Aug; 5(15):2982-2986. PubMed ID: 34342642
[TBL] [Abstract][Full Text] [Related]
12. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
13. A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb.
Wu Y; Chen D; Lu Y; Dong SC; Ma R; Tang WY; Wu JQ; Feng JF; Wu JZ
Cancer Gene Ther; 2022 Feb; 29(2):167-177. PubMed ID: 33514882
[TBL] [Abstract][Full Text] [Related]
14. [Relevance of clonal hematopoiesis for cellular therapies].
Teipel R; von Bonin M; Stölzel F; Schetelig J; Thiede C; Bornhäuser M
Inn Med (Heidelb); 2022 Nov; 63(11):1126-1132. PubMed ID: 36149441
[TBL] [Abstract][Full Text] [Related]
15. Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations.
Mangaonkar AA; Patnaik MM
Am J Hematol; 2023 Jun; 98(6):951-964. PubMed ID: 36938794
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell therapies for lymphoma.
Brudno JN; Kochenderfer JN
Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
[TBL] [Abstract][Full Text] [Related]
17. Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis.
Cao G; Lei L; Zhu X
Medicine (Baltimore); 2019 Oct; 98(42):e17506. PubMed ID: 31626107
[TBL] [Abstract][Full Text] [Related]
18. [CAR-T cells in lymphomas: Current and evolving role].
Messéant O; Houot R
Bull Cancer; 2021 Oct; 108(10S):S28-S39. PubMed ID: 34920805
[TBL] [Abstract][Full Text] [Related]
19. Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.
Ye B; Sheng Y; Zhang M; Hu Y; Huang H
Cancer Lett; 2022 Jul; 538():215691. PubMed ID: 35469959
[TBL] [Abstract][Full Text] [Related]
20. A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.
Zhao H; Wang Y; Yin ETS; Zhao K; Hu Y; Huang H
Front Med; 2020 Dec; 14(6):711-725. PubMed ID: 33259039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
